Be a Smart Investor
Monday, February 27, 2017
Gainers & Losers Of Feb.27: LJPC, NVAX, KTOV, CYCC, ARGS...
La Jolla Pharmaceutical Co.'S phase III trial of LJPC-501 in patients with catecholamine resistant hypotension has met the primary endpoint.
from RTT - Biotech http://ift.tt/2mEOOIS
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment